FDA Expands Use of Lung Cancer Therapeutic
The FDA approved a targeted therapeutic to treat patients with metastatic squamous non-small cell lung cancer.
Progress Against Cancer
The FDA approved a targeted therapeutic to treat patients with metastatic squamous non-small cell lung cancer.
The FDA approved cabozantinib for treating certain patients with the most common form of kidney cancer diagnosed in U.S. adults—renal cell carcinoma.
The FDA approved a new colorectal cancer screening test that uses blood samples to detect tumors.
The FDA approved a treatment for certain patients with chronic lymphocytic leukemia (CLL).
The FDA approved the use of crizotinib for treating patients with advanced non-small cell lung cancer that tests positive for a mutation in the ROS-1 gene.
The FDA expanded the use of an immunotherapy to treat certain patients with follicular lymphoma.
Diets with high amounts of simple carbohydrates appear to increase the risk of lung cancer, especially among people who have never smoked.
The FDA has approved eribulin mesylate for the treatment of one of the most common types of soft tissue sarcoma, liposarcoma.
The U.S. Food and Drug Administration approval provides a new treatment option for patients whose cancer is not responding to crizotinib The U.S. Food and Drug Administration (FDA) has approved the molecularly targeted therapeutic...
The FDA recently added another therapeutic to the armamentarium for oncologists treating certain patients with lung cancer: necitumumab.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More